An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY ·
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well certain blood tests can track the effects of a medicine called lecanemab in people with early Alzheimer's disease. Lecanemab is a treatment that aims to reduce the build-up of harmful proteins in the brain, which are linked to Alzheimer's. The study wants to see if blood tests can accurately show changes in the brain that are confirmed by special brain scans.
People who might be eligible for this study are adults who have early signs of Alzheimer's disease and are being treated with lecanemab. Participants will have blood tests and brain scans to help doctors understand how the treatment is working. This study is currently looking for participants, and it includes adults of all genders within a wide age range. The goal is to find easier ways to monitor Alzheimer’s treatment without needing many scans, making it simpler and less invasive for patients in the future.
Gender
ALL
Eligibility criteria
About First Affiliated Hospital Of Zhejiang University
The First Affiliated Hospital of Zhejiang University is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive network of specialists and state-of-the-art facilities to facilitate groundbreaking studies across various medical disciplines. With a focus on improving patient outcomes and contributing to global medical knowledge, the hospital actively engages in collaborative research initiatives, ensuring rigorous adherence to ethical standards and regulatory compliance. Its dedication to fostering a culture of scientific inquiry underscores its role as a pivotal player in the advancement of medical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported